Assessing potential of psilocybin for depressive disorders
Expert Opinion on Investigational Drugs – October 03, 2023
Source: OpenAlex
Summary
For those battling severe depression, especially when other treatments fail, psilocybin treatment shows distinct promise. This hallucinogen, a key focus in Psychedelics and Drug Studies, appears most suitable for patients with treatment-resistant depression (TRD). While Psychiatry and Medicine explore its therapeutic potential, particularly regarding its psychological effects, understanding the full scope of risks remains crucial. The current evidence suggests a targeted application, prioritizing individuals for whom existing care has proven insufficient.
Abstract
There is still much unknown regarding the risks of psilocybin treatment. When weighing the known risks and benefits of psilocybin treatment against those found in existing standards of care, among patients with depression, patients with treatment-resistant depression (TRD) may be the most suitable candidates for psilocybin treatment at this time.